Abstract Body: Blood pressure (BP) is controlled by an array of cellular pathways. Our prior research revealed that endothelial nitric oxide (NO)-dependent vessel tone and BP are regulated through the RhoBTB1-CUL3 mediated proteasomal degradation of Phosphodiesterase 5 (PDE5). RhoBTB1 is an adaptor protein which delivers protein substrates to the CUL3 E3 ubiquitin ligase for proteasomal degradation. However, the range of protein targets of RhoBTB1 remains unknown. We employed the ascorbate peroxidase (APEX2) proximity labelling system coupled with mass spectroscopy to identify RhoBTB1 targets in A7r5 smooth muscle cells. This analysis identified nearly 75 proteins which putatively bind to the C terminal half of RhoBTB1 (known as B1B2C), the region we previously identified was essential for adaptor function. One of these proteins was RNA binding motif protein 9, known as RBM9 and RbFox2, a key regulator of splicing events. Subsequent co-immunoprecipitation (Co-IP) assays validated the interaction of RbFox2 with RhoBTB1 and its B1B2C domains. Expression of Rbfox2 was increased in response to treatment of A7r5 cells with either MG132, an inhibitor of the proteasome, and MLN4924, an inhibitor of the CUL family. Similarly, RbFox2 expression was increased in CRISPR-Cas9 generated CUL3-deficient HEK293 cells, in aorta isolated from SMC-specific CUL3-deficient mice, and in A7r5 cells expressing an siRNA targeting RhoBTB1. Ang-II treatment of mice, which raised blood pressure by 40 mmHg, also increased RbFox2 expression, presumably through down regulation of RhoBTB1. Targeting RbFox2 by siRNA in A7r5 cells resulted in a decrease in actin fiber formation detected by phalloidin staining. In summary, our findings suggest that RbFox2 regulation may occur through the RhoBTB1-CUL3 proteasomal pathway and may potentially play a mechanistic role in actin cytoskeleton organization and thus arterial stiffness associated with hypertension.